APR 25, 2017 10:00 AM PDT

WEBINAR: Discover Potentially Predictive Immuno-Oncology Biomarkers using Next-Gen Sequencing

Speakers
  • Director of Bioinformatics R&D, Thermo Fisher Scientific
    Biography
      Fiona Hyland is Director of Informatics R&D at Thermo Fisher Scientific. Fiona majored in Genetics as an undergraduate in Trinity College, Dublin, and in Quantitative Genetics (with minors in Statistics and Population Genetics) as a graduate student at Cornell University. Fiona then worked in information technology for several years (in web development, at an internet start-up, and at Nortel Networks), before returning to Biotech, joining Applied Biosystems (subsequently Life Technologies, now Thermo Fisher Scientific).

      For Ion Torrent, Fiona's teams launched tools to help interpret sequencing data in clinical research contexts, including algorithms for tumor-normal analysis, genetic disease, CNV and aneuploidy detection, gene fusion, and genetic annotation.

      Fiona has authored many scientific articles, conference presentations, and patents, has been a reviewer for a range of scientific journals, has been a member of the 1000 Genomes consortium, and the CDC Nex-StoCT II Informatics Consortium and the FDA SEQC Consortium, and has presented widely at scientific conferences.
    • Professor of Pathology at Roswell Park Cancer Institute; President of OmniSeq Precision Medicine Technology
      Biography
        Dr. Morrison is the President, Chief Scientific Officer and Founder of OmniSeq Precision Medicine Technology. He developed the vision for OmniSeq while leading the Center for Personalized Medicine and Division of Molecular Pathology at Roswell Park Cancer Institute.

        Dr. Morrison remains a Professor and program member in Cancer Genetics at Roswell Park Cancer Institute. He was recently awarded the Thomas B. Thomasi Hope Award. This Award is the highest honor Roswell Park bestows to the faculty member whose work has made significant advances in the fight against cancer while brining hope to cancer patients.

        Recognized nationally for his work in translational medicine, Dr. Morrison has authored or co-authored more than 100 peer-reviewed manuscripts with a focus on molecular pathology. His work has been published in leading journals including Nature, Journal of Clinical Oncology and Cancer Research. He recently published a leading work in next generation sequencing of bladder cancer in PNAS.

        Dr. Morrison is a member of the College of American Pathologists and Association of Molecular Pathology. As a board-certified pathologist, Dr. Morrison has led the development of OmniSeq Comprehensive - a next generation sequencing technology that focuses on DNA-Seq and RNA-Seq to increase throughput with increased accuracy, identifying therapeutically actionable variants in cancer patients.

        Dr. Morrison received his Doctorate in Veterinary Medicine from the Ohio State University College of Veterinary Medicine followed by his Doctorate in Medicine from the University of Kentucky. He completed his residency at the Ohio State University Medical Center.

      Abstract

      DATE: April 25, 2017
      TIME: 10:00am PT, 1:00pm ET

      Immunotherapy has emerged as one of the most promising options for the future treatment of a growing number of cancers and is touted to be the next revolution in our fight against this complex disease. One of the most effective modalities of treatment, thus far, has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors.

      Current biomarkers and immunohistochemistry (IHC) assays are not accurate predictors of which individuals are most likely to respond or benefit from immunotherapeutic agents, thus prompting the need to identify better biomarkers that can guide therapy selection in the future. 

      Next-generation sequencing (NGS) offers clinical researchers a cost-efficient and rapid way of analyzing multiple targets simultaneously from as little as 10ng of total RNA isolated from formalin-fixed, paraffin-embedded (FFPE) samples.  

      In this webinar, our speakers will show how Thermo Fisher Scientific’s Oncomine Immune Response Research Assay enables the interrogation of gene targets that are critical for research into immune response.
       
      Topics to be covered:

      • Fiona Hyland will describe how the content for a new gene expression NGS-based assay was carefully selected and will compare its performance against other assay(s) available on the market.
      • Dr. Carl Morrison will describe a verification study for establishing the performance of the new Oncomine Immune Response Research Assay in a clinical research lab.

      Key learning objectives for attendees:

      • How to improve immuno-oncology biomarker discovery using NGS
      • Benefits of applying a targeted gene-expression based approach for studying the tumor microenvironment
      • How to implement the Oncomine Immune Response Research Assay in a clinical research lab 

      Who should attend:

      • Scientists involved in biomarker discovery and drug development 
      • Contract Research Organizations focused on oncology services
      • Immunology and oncology translational/clinical research laboratories interested in adopting NGS


      For Research Use Only. Not for use in diagnostic procedures.


      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      MAR 18, 2021 8:00 AM PDT
      C.E. CREDITS
      MAR 18, 2021 8:00 AM PDT
      DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
      APR 25, 2017 10:00 AM PDT

      WEBINAR: Discover Potentially Predictive Immuno-Oncology Biomarkers using Next-Gen Sequencing


      Specialty

      Cancer Research

      Molecular Diagnostics

      Molecular Biology

      Cancer Diagnostics

      Clinical Diagnostics

      Immunology

      Biomarkers

      Genomics

      Biotechnology

      Genetics

      Cancer Therapeutics

      Cell Biology

      Oncology

      Clinical Research

      Laboratory Testing

      Geography

      North America66%

      Europe14%

      Asia11%

      South America4%

      Oceania1%

      Africa1%

      Registration Source

      Website Visitors100%

      Job Title

      Executive17%

      Scientist14%

      Facility/Department Manager12%

      Research Scientist10%

      Student9%

      Educator/Faculty7%

      Lab Management6%

      Medical Laboratory Technician5%

      Medical Doctor/Specialist5%

      Marketing/Sales3%

      Post Doc3%

      Clinical Laboratory Scientist2%

      Biologist2%

      Chemist1%

      QC/QA1%

      Consultant1%

      Pathologist1%

      Organization

      Biotech Company9%

      Academic Institution8%

      Clinical Laboratory5%

      Hospital5%

      Life Science Company3%

      Research Institute3%

      Pharmaceutical Company3%

      Ambulatory Care2%

      Medical School2%

      Medical Center2%

      Industrial Company1%

      Consultant1%

      Government1%

      Medical Device Company1%

      Other4%


      Show Resources
      Loading Comments...
      Show Resources
      Attendees
      • See more